GenScript Intelligence Profile

genscript.comLast reviewed: October 20, 2026Research coverage: 94%

Overall data confidence:Unknown

Identity confidence

High

8 of 10 identity fields independently documented

Corporate continuity

Continuity supported — domain genscript.com registered 2001-10-20 and continuously associated with this company, which states it was founded in New Jersey in 2002; the site has operated as the group's ordering and services platform through its 2015 HKEX listing to the present, and vendor documents (catalogs, manuals, brochures) referencing the same domain, address, and contact channels span from the 2000s to current 2025-era materials. Site live today.

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

7 of 7 testing fields documented

Transaction transparency

High

5 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 94%. Our research on GenScript remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Entity status researched (entity_status)
Public summary reviewed

Overview#

GenScript is a large, established life-science CRO that passes the fit gate clearly: it sells custom peptide synthesis (PepPower platform, up to 200 residues, mg-to-kg scale, 300+ modifications, peptide libraries, and RUO-to-cGMP tiers including neoantigen and API work) plus catalog peptides, through genscript.com (domain registered 2001-10-20, registrar DNSPod). Its U.S. presence is real and documented: GenScript USA Inc. at 860 Centennial Ave., Piscataway, NJ 08854 — the address in its parent's HKEX annual report, its own 'registered address' statement, and an FDA EUA letter naming it as the U.S. subsidiary. The structure above it must be read honestly: the listed parent, Genscript Biotech Corporation (HKEX: 1548), is a Cayman Islands-incorporated holding company (incorporated 21 May 2015; listed 30 Dec 2015) with operational headquarters in Nanjing, China, over a business founded in New Jersey in 2002 by Fangliang Zhang, Ye Wang, and Luquan Wang. All defined U.S. regulatory searches returned No Record Found: no FDA warning letter, recall, or import alert, no FTC action, no state AG action — the FDA record found is an authorization (2020 cPass EUA), not an enforcement action. Documented legal history: (1) as PLAINTIFF, GenScript USA won a $10M+ NJ jury verdict (2014, upheld 2015) against GeneWiz for trade-secret misappropriation; (2) a PRC customs investigation (2020-2022) into suspected import/export violations in which founder Zhang was arrested — closed by the Zhenjiang Procuratorate on 2 May 2022 with NO charges against any entity or individual and no criminal liability; (3) U.S. legislative scrutiny — House Select Committee letters (May 2024, renewed July 2025) requesting FBI/DNI briefings on GenScript in the BIOSECURE Act context; GenScript is not a company named in the BIOSECURE Act, no designation or finding has resulted, and this is news/legislative context, not enforcement. Testing model differs from RUO storefronts: QC is in-house (ISO 9001 RUO; cGMP tiers with batch records and batch-specific COAs covering HPLC purity and MS identity, expanded panels for cGMP), COAs are delivered with orders / downloadable by purchasers, and there is no public COA-verification portal and no independent third-party lab. Commercial model is institutional: orders by formal PO or credit card; no consumer refund/returns policy is published for custom services, though peptide turnaround guarantees ('or your money back' on the 5/7-business-day claim, delay compensation) and a faulty-product replace-or-credit guarantee for catalog products are documented. Open items are narrow: NJ SoS entity standing and registered agent were not retrievable in this pass (interactive registry), so both are recorded Unknown rather than inferred. No High/Critical severity findings: no FDA/FTC enforcement, no recalls, and no impersonation indicators — the domain (2001) predates and matches the documented corporate history.

Company Identity#

Vendor Brand NameGenScript

HighSource: GenScript Bio Reagent Center — Custom Peptide Services (PepPower platform)

Primary Website Domaingenscript.com

ModerateSource: GenScript — official website (intake domain confirmation)

Legal Entity NameGenScript USA Inc. (U.S. operating entity); parent: Genscript Biotech Corporation — an exempted company incorporated in the Cayman Islands with limited liability, listed on the Hong Kong Stock Exchange (stock code 1548)

HighSource: FDA Emergency Use Authorization letter for cPass SARS-CoV-2 Neutralization Antibody Detection Kit, addressed to GenScript USA Inc., 860 Centennial Ave, Piscataway, NJ 08854, describing it as 'a subsidiary of Genscript Biotech Corporation' (FDA letter hosted as PDF)

State of RegistrationNew Jersey (GenScript USA Inc., the U.S. operating entity); the listed parent Genscript Biotech Corporation is incorporated in the Cayman Islands

ModerateSource: GenScript promotion terms — 'Promoter. GenScript USA Inc, with its registered address at 860 Centennial Ave, Piscataway, New Jersey 08854'

Entity StatusNot independently verified

UnknownSource: MIRA Inform credit report — GENSCRIPT USA INCORPORATED (612774): HQ 860 Centennial Ave., Piscataway, NJ 08854; corporate-registry extract listing a New Jersey (US) record dated 18 May 2009 and Massachusetts branch records from Nov 2019

Incorporation / Formation Date2002 (operating business founded in New Jersey, U.S.); the listed parent Genscript Biotech Corporation was incorporated on 21 May 2015 in the Cayman Islands as the group's listing vehicle, and a third-party corporate-registry extract dates a New Jersey record for GENSCRIPT USA INCORPORATED to 18 May 2009

ModerateSource: GenScript Biotech Corporation Interim Report 2025 — corporate information: Company incorporated 21 May 2015 in the Cayman Islands; shares listed on HKEX Main Board since 30 December 2015; ultimate holding company Genscript Corporation (GS Corp), incorporated in the U.S.

Named Principals / ManagersParent-company board and leadership per the 2024 annual report and company releases: Executive Directors — Dr. Fangliang Zhang (Dr. Frank Zhang, co-founder), Mr. Jiange Meng (Mr. Robin Meng, Chairman), Ms. Ye Wang (Ms. Sally Wang, co-founder, President), Dr. Li Zhu (Chief Strategy Officer); Non-Executive Director Dr. Luquan Wang (Dr. Larry Wang, co-founder); Rotating Chief Executive Officer Ms. Weihui Shao (Ms. Sherry Shao). The business was co-founded in 2002 by Fangliang Zhang, Ye Wang, and Luquan Wang. Officers of the U.S. subsidiary GenScript USA Inc. specifically are not separately listed in the sources reviewed.

ModerateSource: GenScript Biotech Corporation Annual Report 2024 (HKEX filing, via Quartr) — corporate information: U.S. principal place of business 860 Centennial Avenue, Piscataway, NJ 08854; stock code 1548; board of directors

Registered AgentNot independently verified

UnknownSource: GenScript promotion terms — 'Promoter. GenScript USA Inc, with its registered address at 860 Centennial Ave, Piscataway, New Jersey 08854'

Operating Address860 Centennial Ave., Piscataway, NJ 08854, USA — U.S. headquarters / principal place of business in the U.S. of GenScript USA Inc.

HighSource: GenScript Biotech Corporation Annual Report 2024 (HKEX filing, via Quartr) — corporate information: U.S. principal place of business 860 Centennial Avenue, Piscataway, NJ 08854; stock code 1548; board of directors

Address ConsistencyConsistent — the U.S. address 860 Centennial Ave., Piscataway, NJ 08854 appears identically across the vendor's current site and brochures, its promotion terms (where it is called the company's 'registered address'), the parent company's 2024 annual report (listed as 'Principal Place of Business in the U.S.'), the FDA's EUA letter to GenScript USA Inc., and third-party corporate records. One historical variation: an older cGMP peptide flyer gives 120 Centennial Ave., Piscataway — a superseded address on the same street, not a conflicting current address.

HighSource: GenScript promotion terms — 'Promoter. GenScript USA Inc, with its registered address at 860 Centennial Ave, Piscataway, New Jersey 08854'

Domain and Digital Identity#

Domain Registration Date2001-10-20

HighSource: Verisign RDAP — genscript.com

Domain Ownership / Registrar Change HistoryPartially known — current registrar is DNSPod, Inc. (IANA Registrar ID 1697; a Tencent company); RDAP record last changed 2024-05-29; registration expires 2032-10-20; nameservers NS3.DNSV4.COM and NS4.DNSV4.COM; domain status 'active'. Registrant identity is not disclosed in the RDAP record, and earlier registrar/ownership history was not established in this pass.

LowSource: Verisign RDAP — genscript.com

Website ContinuityContinuity supported — domain genscript.com registered 2001-10-20 and continuously associated with this company, which states it was founded in New Jersey in 2002; the site has operated as the group's ordering and services platform through its 2015 HKEX listing to the present, and vendor documents (catalogs, manuals, brochures) referencing the same domain, address, and contact channels span from the 2000s to current 2025-era materials. Site live today.

ModerateSource: Verisign RDAP — genscript.com

Contact Channel IntegrityPublished channels are consistent across the site and vendor documents: order@genscript.com for orders, peptide@genscript.com for peptide services, info@genscript.com for general inquiries, phone 1-732-885-9188, toll-free 1-877-436-7274, fax 1-732-210-0262, plus an online quote/ordering form. The same phone/fax numbers and the Piscataway address recur in catalogs, brochures, and product manuals spanning many years. No conflicting contact details found.

HighSource: GenScript Bio Reagent Center — Custom Peptide Services (PepPower platform)

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of fda.gov — no FDA warning letter naming GenScript, GenScript USA Inc., or genscript.com

FDA Recall / Safety Action HistoryNo Record Found in the defined search

ModerateSource: Defined web search of fda.gov — no FDA warning letter naming GenScript, GenScript USA Inc., or genscript.com

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search of fda.gov — no FDA warning letter naming GenScript, GenScript USA Inc., or genscript.com

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of ftc.gov — no FTC action naming GenScript

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search — GenScript (attorney general / state regulator / recall / import alert, as applicable per field)

Relevant Civil LitigationGenScript USA, Inc. v. GeneWiz, Inc. (New Jersey state court) — GenScript as PLAINTIFF: in October 2014 a jury returned a verdict of more than $10 million in GenScript's favor, finding that GeneWiz had illegally obtained and used GenScript's gene-synthesis trade secrets and had improperly hired/solicited more than 20 GenScript employees via former employee Ping 'Mark' Yang to launch a competing gene synthesis business; on 20 February 2015 Superior Court Judge Arthur Bergman denied GeneWiz's post-trial motions, allowing the verdict to stand. No civil litigation against GenScript entities of directory relevance surfaced in the defined search beyond this case, in which GenScript was the prevailing plaintiff.

HighSource: BioSpace, 9 Dec 2014 — GenScript USA, Inc. awarded $10 million+ jury verdict in trade secret case against GeneWiz, Inc. (NJ state court)

Criminal / Injunctive ProceedingsOne concluded foreign criminal proceeding is documented; no U.S. criminal or injunctive proceeding was found. PRC Customs Anti-Smuggling Department investigation (2020-2022): Chinese customs inspected GenScript group premises in Nanjing and Zhenjiang on 17 September 2020 over suspected import/export regulation violations; co-founder Dr. Fangliang Zhang was placed under residential surveillance and later arrested for the suspected offence of smuggling goods prohibited by PRC import/export regulations, as were two employees involved in import/export activities; no formal charges had been filed at that stage. The matter was handed to the Zhenjiang Municipal People's Procuratorate in May 2021, and on 2 May 2022 the Procuratorate decided NOT to bring any charge against any entity or individual — per the company's HKEX announcement, none of the company, its subsidiaries, Dr. Zhang, or the employees has or will have any criminal liability in respect of the investigation (a RMB7.0 million deposit was made to the authority in connection with it). This is a PRC proceeding, not a U.S. action, and it ended without charges.

HighSource: GenScript Biotech Corporation HKEX announcement, 25 May 2021 — Update on the Investigation: PRC customs investigation completed, matter handed to Zhenjiang Municipal People's Procuratorate; no formal charges made or filed at that date

Testing and COA Evidence#

Public COA AvailabilityCOAs are not publicly posted for pre-purchase browsing — this is a B2B services model: a Certificate of Analysis is a delivered document supplied with each custom peptide / synthesis order (default QC package: purity and MS for RUO; expanded COA, plus TSE/BSE statement and Certificate of Compliance, for cGMP tiers). For catalog products, a purchaser can download the COA from the GenScript website; a non-purchaser must request COA details by email. No open public COA library was found.

ModerateSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

Batch / Lot SpecificityEstablished — production is batch-based and batch-specific: the cGMP peptide service documents batch records for each manufacturing step and batch traceability of all raw materials, and delivers a batch-specific Certificate of Analysis (for cGMP: appearance, identity by MS/AAA/HPLC, purity and related substances by HPLC, assay, endotoxins, bioburden, etc.). For catalog products, GenScript's FAQ ties COAs to the product's lot number, which customers are asked to cite in support queries.

ModerateSource: GenScript cGMP Peptide Service flyer (historical) — cGMP COA contents (identity by MS/AAA/HPLC, purity by HPLC, endotoxins, bioburden); historical address 120 Centennial Ave., Piscataway, NJ

Independent Laboratory IdentityNo independent third-party laboratory — peptide QC testing is performed in-house by GenScript itself under its own quality management systems (ISO 9001 for research-use-only production; cGMP-compliant systems for IND/cGMP tiers, with batch records and QA release). Vendor materials name no external laboratory as the issuer of peptide COAs; the COA issuer is GenScript's own QC function.

ModerateSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

COA Verification StatusNot verifiable through a public COA-verification portal — no lot/COA lookup or authentication system for third parties was found. Purchasers can download the COA for a purchased catalog product from the GenScript website; non-purchasers must request COA details by email. Custom-synthesis COAs are delivered with the order rather than published for independent authentication.

ModerateSource: GenScript Recombinant Proteins Technical FAQ — COA downloadable from website by purchasers / by email request otherwise; faulty products replaced or credited at full purchase price during guarantee period

Test RecencyPer-order by design, but no dated sample COA was publicly inspected in this pass: because COAs are generated at production for each current order/batch (rather than posted), the vendor's testing output is current with its order flow, and its peptide QC documentation is presented in a current (2025-era) service brochure. However, no individual recent COA with a visible test date could be examined publicly, so recency is recorded at low confidence pending direct COA-date sampling.

LowSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

Testing CoverageVendor-stated coverage is service-wide: every custom peptide order is delivered with QC documentation — default RUO QC package is HPLC purity and MS identity, with optional analyses including solubility testing, TFA counter-ion exchange/detection, endotoxin control and analysis, amino acid analysis, peptide content analysis, moisture, stability testing, and peptide sequencing; cGMP tiers add a full COA panel (appearance, solubility, identity by MS/AAA/HPLC, purity and related substances by HPLC, assay, TFA, counterion, water, mass balance, specific rotation, residual solvents, bacterial endotoxins, bioburden). Quality systems: ISO 9001 QMS for RUO production, cGMP-compliant QMS for IND/cGMP tiers, with batch records required at the cGMP tiers. Coverage figures are the vendor's own service specifications; no independent test index coverage of GenScript was assessed.

ModerateSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

Evidence ConsistencyEvidence is broadly consistent, with structural complexity a reader must understand rather than an inconsistency: (1) the brand 'GenScript' is operated in the U.S. by GenScript USA Inc. of Piscataway, NJ, while the listed parent, Genscript Biotech Corporation, is a Cayman Islands-incorporated, Hong Kong-listed holding company whose operational headquarters is in Nanjing, China — sources variously describe the group as 'founded in New Jersey in 2002' and 'headquartered in Nanjing', both of which are supported for different levels of the structure; (2) the current U.S. address (860 Centennial Ave.) is uniform across current sources, superseding a historical 120 Centennial Ave. address in older materials; (3) leadership titles have changed over time (founder Fangliang Zhang was chairman/CEO, stepped back after the 2020 PRC investigation; Jiange 'Robin' Meng is chairman in the 2024 annual report and Sherry Shao is rotating CEO). No falsified-testing-evidence indicators were found; quality claims (ISO 9001 RUO QMS, cGMP-compliant tiers) are stated consistently across the vendor's peptide materials.

Payment, Refund and Shipping#

Accepted Payment MethodsFormal purchase order (PO) or credit card — orders may be placed by phone, email, fax, or through GenScript's secure online ordering system, per the vendor's Company Overview ordering section. This is a B2B/B2-institutional model; no consumer checkout, cryptocurrency, or wallet payment methods are offered.

HighSource: GenScript Company Overview — Quotations and Ordering: orders by phone, email, fax, or online with a formal PO (Purchase Order) or credit card

Refund / Return PolicyPartially established — no general published returns/refund policy for custom synthesis services was located on the vendor's site. Documented guarantee remedies that function in place of one: the current peptide brochure markets '5/7 business days production or your money back' and delay compensation of 10% of the delayed item's value per business day up to 50% for the guaranteed-turnaround service; and the vendor FAQ states that if a catalog product is found faulty during its guarantee period, GenScript will replace the product or credit the account with the full purchase price. Custom-made peptides are made to order against a PO/credit card, and no return right for them is published in sources reviewed.

LowSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

Shipping & Fulfillment RepresentationsVendor representations: peptides are shipped as lyophilized powder, normally at room temperature (liquid formats on dry ice); published peptide turnaround representations are 5 business days (rush, up to 25 aa), 6 business days (fast), and 10 business days (regular, up to 200 aa), with typical custom synthesis described as about 2-3 weeks depending on length/complexity, guaranteed-quantity delivery for orders under 20 mg, and delay compensation (10% of the delayed item's value per business day, capped at 50%) on the guaranteed-turnaround tier. The vendor's bio-reagent services page states its team has delivered over 90% of all orders on time. Turnaround figures are production times and exclude shipping time per the vendor's own notes.

ModerateSource: GenScript Peptide Service Brochure — RUO to cGMP peptide synthesis, QC packages, delivered documentation (COA), turnaround guarantees

Terms / Policy StabilityCore commercial terms appear longstanding and stable: the ordering model (orders by phone/email/fax/online against a formal PO or credit card, via the secure online ordering system) is stated in the same terms in the vendor's older catalog materials and its current Company Overview, and the Piscataway address, phone, and fax in current policy/promotion terms match documents going back many years. The material change in the period is corporate, not terms-related (the 2015 HKEX listing structure and the 2024 Legend deconsolidation). Intake pass — future refresh cycles can diff the vendor's full Terms of Sale directly.

LowSource: GenScript Company Overview — Quotations and Ordering: orders by phone, email, fax, or online with a formal PO (Purchase Order) or credit card

Customer Complaint PatternNo Record Found in the defined search — no BBB complaint profile or documented customer-complaint pattern for GenScript was located; the vendor is a B2B life-science CRO selling to institutions, and review/complaint coverage of the kind seen for consumer peptide storefronts does not exist for it in sources searched. Vendor-published customer testimonials are positive but are self-published marketing and are not counted as complaint evidence. A 2018 short-seller report (Flaming Research) alleged data problems in a Legend Biotech CAR-T program; GenScript denied the allegations — recorded here only as a contested allegation, not a customer complaint or a regulator finding.

LowSource: Defined web search — GenScript (attorney general / state regulator / recall / import alert, as applicable per field)

Material Changes#

No material changes recorded.

Sources#

U.S. House Select Committee on the CCP — letter to FBI Director and DNI requesting a briefing on GenScript Biotechnology and its segments Bestzyme, Legend Biotech and ProBio (30 May 2024)Tier 1 · AuthoritativeGovernment RecordAuthoritative

Retrieved: October 20, 2026